Abstract

Burkholderia pseudomallei, the causative agent of melioidosis has been recognized by CDC as a category B select agent. Although substantial efforts have been made for development of vaccine molecules against the pathogen, significant hurdles still remain. With no licensed vaccines available and high relapse rate of the disease, there is a pressing need for development of alternate protection strategies. Antibody-mediated passive protection is promising in this regard and our primary interest was to unravel this frontier of specific mAbs against Burkholderia pseudomallei infections, as functional characterization of antibodies is a pre-requisite to demonstrate them as protective molecules. To achieve this, we designed our study on in vitro-based approach and assessed two mAbs, namely BURK24 and BURK37, reactive with outer membrane proteins and lipopolysaccharide of the pathogen respectively, for their ability to manifest inhibitory effects on the pathogenesis mechanisms of B. pseudomallei including biofilm formation, invasion and induction of apoptosis. The experiments were performed using B. pseudomallei standard strain NCTC 10274 and a clinical isolate, B. pseudomallei 621 recovered from a septicemia patient with diabetic ailment. The growth kinetic studies of the pathogen in presence of various concentrations of each individual mAb revealed their anti-bacterial properties. Minimal inhibitory concentration and minimal bactericidal concentration of both the mAbs were determined by using standards of Clinical and Laboratory Standards Institute (CLSI) and experiments were performed using individual mAbs at their respective bacteriostatic concentration. As an outcome, both mAbs exhibited significant anti-Burkholderia pseudomallei properties. They limited the formation of biofilm by the bacterium and completely crippled its invasion into human alveolar adenocarcinoma epithelial cells. Also, the mAbs were appreciably successful in preventing the bacterium to induce apoptosis in A549 cells. The present study design revealed the protection attributes possessed by BURK24 and BURK37 that has to be further substantiated by additional in vivo studies.

Highlights

  • Burkholderia pseudomallei infections, collectively termed as melioidosis, are endemic in Southeast Asia and northern Australia

  • Immunization and Generation of Monoclonal antibodies (mAbs) Gradual increase in antibody titer was observed in BALB/c mice sera after each immunization, as revealed by indirect plate ELISA

  • This indicated that the outer membrane proteins (OMPs) extract used was immunogenic resulting in antibody response in immunized mice

Read more

Summary

Introduction

Burkholderia pseudomallei infections, collectively termed as melioidosis, are endemic in Southeast Asia and northern Australia. In Thailand, B. pseudomallei infections are predominantly manifested as community-acquired septicaemia. The infection recommends longer course of intensive antibiotic therapy that comprises of intravenous administration of ceftazidime for 10 days, followed by oral antimicrobial therapy comprising of trimethoprim and sulfamethoxazole for 3–6 months [3]. Intrinsic resistance of B. pseudomallei to multiple drugs and emergence of resistant strains against the above mentioned antibiotic regimen has become a challenge for curing melioidosis [5,6,7,8]. No substitutional protecting molecules or human vaccines for the disease currently exist. There is a high priority for development of alternative antimicrobial molecules that can efficiently confer passive protection against the disease among the susceptible hosts. Generation of immediate protection in infected hosts is required in order to overcome B. pseudomallei infections

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call